Indication
In combination with bevacizumab for the treatment of adult patients with advanced or unresectable hepatocellular carcinoma (HCC) who have not received prior systemic therapy.
Medicine details
- Medicine name:
- atezolizumab (Tecentriq)
- SMC ID:
- SMC2349
- Pharmaceutical company
- Roche
- BNF chapter
- Malignant disease and immunosuppression
- Submission type
- Full
- Publication due date:
- 12 July 2021
- SMC meeting date:
- 01 June 2021
- Patient group submission deadline:
- 05 April 2021